Jasper Therapeutics
Recruiter Contact
Daniela Iwanski
V.P | Executive Recruiter
480-718-6201
Recruiter Contact
Jacqueline “Jack” Johnson
V.P | Executive Recruiter
480-718-6191
About
Jasper Therapeutics
Meet The
Leadership Team
Chief Executive Officer
Ronald Martell
Chief Operating Officer
Jeet Mahal
Chief Medical Officer
Edwin Tucker, M.D.
Vice President, Human Resources
Matt Ford
Featured
Articles
Pipeline & Media-
Jasper's Development Pipeline
To date, briquilimab has been evaluated in more than 145 healthy volunteers and patients. This humanized antibody is being studied in Jasper-sponsored clinical trials in multiple diseases.
Jasper's Q3 Update
“We achieved several significant milestones in our mast cell development programs in recent months, highlighted by positive initial data from our SPOTLIGHT study in CIndU,” said Ronald Martell, President and Chief Executive Officer of Jasper. “We were very excited to present our first dataset evaluating briquilimab in a mast cell disease, which showed that over 90% of patients treated in the 40mg and 120mg dose cohorts achieved a clinical response, with no serious adverse events (SAEs) and no grade 3 or higher adverse events (AEs) reported.
Jasper Therapeutics Announces Further Expansion of Clinical Program
I am very pleased with the ability of our clinical and regulatory teams to efficiently advance our clinical development plan in support of generating a robust data set in chronic urticaria,” said Ronald Martell, President and Chief Executive Officer of Jasper. “The addition of the 360mg single-dose cohort in the BEACON study in CSU will allow us to evaluate another potential loading dose leveraging the ongoing clinical trial, and the rollover extension study will allow us to gather longer-term safety and efficacy data at therapeutic doses for patients in both BEACON and SPOTLIGHT. The expanded breadth of clinical data provided in CSU and CindU should further support optimal biologic dosing in our registrational studies, planned to commence in the second half of 2025.”